// App-Quantinova.ai

Sa1989 : Pharmacokinetics of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative Colitis: Results From a Randomized, Multicenter, Open-Label Phase 3 Study

Researchers

Presenter

  • Zhenhua Xu

Principal Investigators

  • Lakshmi Damaraju

  • Marion Blank

  • Jewel Johanns

  • Anne M. Griffiths

  • Joyce A. Ford

  • Honghui Zhou

  • Cynthia A. Guzzo

  • Hugh M. Davis

  • Jeffrey S. Hyams

Medical Centers

  • Hospital for Sick Children, Toronto, ON, Canada

  • Connecticut Children's Medical Center, Hartford, CT

Locations

  • United States

  • Canada

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Infliximab

  • Mesalamine

  • 6-mercaptopurine

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved